Gutierrez-Delgado, Cristina
Galindo-Suárez, Rosa-María
Cruz-Santiago, Cesar
Shah, Koonal
Papadimitropoulos, Manny
Feng, Yan
Zamora, Bernarda
Devlin, Nancy
Article History
Accepted: 14 March 2021
First Online: 26 June 2021
Declarations
:
: This study received unrestricted financial support from the <i>Asociación Mexicana de la Industria de Investigación Farmacética</i> (AMIIF) AC and in-kind support from the EuroQol Group for initial training on the EQ-5D-5L valuation protocol of CG, RG, and CC, and access to the EQ-VT tool for the study.
: ND, KS, and YF are members of the EuroQol Group. CG started the project as member of the Economic Analysis Unit at the Mexican Secretariat of Health. However, she left her position in 2019. RG started the project as a member of General Health Council. However, she left her position in November 2018. MP and RG are currently employees of the pharmaceutical industry.
: The study received ethical approval <i>IMSS/DPM/UEIPS/CIS/2128/2018</i> from the National Committee of Ethics and Bioethics and the National Coordination of Research in Health of the Mexican Institute of Social Security and was conducted in accordance with the Declaration of Helsinki.
: Informed consent was obtained from all individual respondents included in the study. Respondents were informed about their freedom of refusal. Anonymity and confidentiality were maintained throughout the research process.
: Not applicable.
: Not applicable.
: Not applicable.
: The study was conceived by CG, RG, CC, KS, MP, and ND. BZ, YF, and KS performed the descriptive data analysis. BZ and YF undertook the econometric modelling. CG, KS, ND, BZ, and YF developed the statistical analysis plan. KS and ND reviewed the modelling output. All authors provided their intellectual inputs into the manuscript; CG produced the first draft of the paper, which KS and ND edited. All authors read and approved the final manuscript.